Download this page’s company profile as a PDF here
Download GNA’s media images here
GNA Biosolutions GmbH was founded in 2010 as a spin-off from Ludwig-Maximilians-Universität, Munich. As a molecular technology developer of instruments, OEM modules, and ultrafast molecular assays, GNA Biosolutions aims to deliver timely, reliable and actionable results for industry and research partners across the fields of medical diagnostics, biosecurity, food safety, and life sciences.
Initial investors in GNA Biosolutions included Mey Capital Matrix and KfW’s ERP Start-up-Fund. In 2015, GNA Biosolutions closed a financing round with additional investment partners (Robert Bosch Venture Capital, SHS, Unternehmer TUM, and btov Partners). The fresh capital was used to spur product development and begin commercialization.
GNA Biosolutions’ first product, the Pharos V8 instrument, is revealed in November 2017 at the Medica Trade Fair in Düsseldorf, Germany. The Pharos V8 delivers ultrafast nucleic acid detection, with signals resulting in 10 minutes or less, and it allows users to bring their lab-developed tests on an open platform.
Within the last years, GNA Biosolutions has established a strong partner network in the field of infectious diseases, amongst them diagnostic companies as well as renowned universities and institutes around the world.
GNA Biosolutions’ core technology is Pulse Controlled Amplification (PCA), a ground-breaking nucleic acid detection technology created using nanomaterials. PCA operates on the same principles of DNA replication as conventional PCR (Polymerase Chain Reaction), which has been a cornerstone of molecular biology for the last 30 years. PCA however, achieves controlled temperature cycles with energy-converting nanomaterials, in order to drastically shorten PCR reaction times, overcoming a key limitation of conventional PCR. PCA can deliver results for nucleic acid detection within minutes, and accelerates molecular laboratory workflows.
“Our goals are to speed up time to results in diagnostic testing, to help reduce costs and to make molecular technologies amenable to as many settings as possible”, says CEO Dr. Frank Krieg-Schneider. “By combining our technology with licensing opportunities and development services we cover a lot of ground in terms of providing value for our customers and delivering what they are looking for in a partner.”
Since the invention of PCR, temperature control has been a bottleneck in developing ultrafast molecular assays. With PCA, application of molecular testing can potentially be applied to multiple time-sensitive settings including the Point of Care (POC), biosecurity and food safety. In parallel to the Pharos V8 instrument, GNA Biosolutions is developing platforms to deliver ultrafast, portable and easy-to-use applications, with additional products launches coming soon.
For all inquiries regarding media and communications, please contact , or call +49 089 998207 180.